Logo
Make a donation
Make a donation

First leukemia research center in France

...

Our themes

Acute lymphoblastic leukemia

Acute myeloid leukemia

Myeloproliferative neoplasms

Myelodysplastic syndromes

Leukemia predisposition syndromes

Acquired and congenital bone marrow failure

Acute lymphoblastic leukemia

Acute myeloid leukemia

Myeloproliferative neoplasms

Myelodysplastic syndromes

Leukemia predisposition syndromes

Acquired and congenital bone marrow failure

The Leukemia Institute: key figures

1st

leukemia treatment and research center in France

16

research teams

10

clinical departments

4

clinical laboratories

Our research teams

Our areas of research

Area 1: MECHANISMS

Basic biology

  • Deciphering the diversity of leukemias using a multiomics approach
  • Identifying intrinsic vulnerabilities of leukemia
  • Exploring the cellular consequences of therapeutic stresses

Area 2: MICROENVIRONMENT

Stem cells and microenvironment

  • Studying cellular interactions between leukemia cells, stroma, and immune effectors
  • Exploring the cellular consequences of therapeutic stresses

Area 3: PRECISION

Therapeutic agents and combinations

  • Testing innovative treatments on primary cells or preclinical models
  • Identifying promising treatment combinations and validating biomarkers

Area 4: PREDISPOSITION

Prevention and precision medicine

  • Identifying patients with germline predisposition
  • Conducting longitudinal somatic studies

Area 5: TRIALS

Early clinical trials

  • Developing innovative trials for precision medicine
  • Integrating biological data into clinical trials

Area 6: CARE

Improving care pathways

  • Implementing a post-treatment follow-up program
  • Exploring quality of life measures with patient associations

Scientific publications

A spatial atlas of human gastrointestinal acute GVHD reveals epithelial and immune dynamics underlying disease pathophysiology

Nofar Azulay & al, Science Translational Medicine, 2025

A spatial atlas of human gastrointestinal acute GVHD reveals epithelial and immune dynamics underlying disease pathophysiology
Read the publication
PPARγ agonists promote the resolution of myelofibrosis in preclinical models

Lambert J & al, J Clin Invest, 2021

PPARγ agonists promote the resolution of myelofibrosis in preclinical models
Read the publication
Developmental interplay between transcriptional alterations and a targetable cytokine signaling dependency in pediatric ETO2::GLIS2 leukemia

Verónica Alonso-Pérez & al, Molecular Cancer, 2024

Developmental interplay between transcriptional alterations and a targetable cytokine signaling dependency in pediatric ETO2::GLIS2 leukemia
Read the publication

Our clinical trials

Open-label study to evaluate the long-term safety of BCX9930 monotherapy in patients with paroxysmal nocturnal hemoglobinuria who have previously received BCX9930 in a BioCryst-sponsored study

Randomized prospective Phase III clinical trial comparing HLA 10/10 matched unrelated donor allogeneic hematopoietic stem cell transplantation and haploidentical transplantation after myeloablative conditioning regimen.

Open-label, randomized, non-comparative, multicenter Phase I/II clinical trial evaluating the safety and efficacy of SMART101 following a partially compatible peripheral blood stem cell transplantation and post-transplant cyclophosphamide administration in patients with blood cancer.

National Observatory for Bone Marrow Failure
Creation of a prospective clinical and biological database and a biological sample collection.

Cooperative groups

Logo fondateur
Logo fondateur
Logo fondateur
Logo fondateur
Logo fondateur

Host foundation and founding members